Assuntos
Doença Cardíaca Carcinoide/patologia , Neoplasias Cardíacas/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Doença Cardíaca Carcinoide/tratamento farmacológico , Neoplasias Cardíacas/tratamento farmacológico , Septos Cardíacos/patologia , Ventrículos do Coração/patologia , Humanos , Neoplasias Intestinais/patologia , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/secundário , Masculino , Pessoa de Meia-IdadeAssuntos
Tumor Carcinoide/patologia , Neoplasias do Mediastino/patologia , Neoplasias do Timo/patologia , Adrenalectomia , Hormônio Adrenocorticotrópico/sangue , Idoso , Tumor Carcinoide/sangue , Tumor Carcinoide/etiologia , Síndrome de Cushing/complicações , Síndrome de Cushing/cirurgia , Progressão da Doença , Humanos , Masculino , Neoplasias do Mediastino/sangue , Neoplasias do Mediastino/etiologia , Estadiamento de Neoplasias , Neoplasias do Timo/sangue , Neoplasias do Timo/etiologia , Tomografia Computadorizada por Raios XRESUMO
There has been a dramatic improvement in outcomes for patients who have colon cancer over recent years. These improvements have come about largely because of the availability of new chemotherapy agents (irinotecan, oxaliplatin and capecitabine) and new biologic agents (bevacizumab and cetuximab). Large, well-designed clinical trials have resulted in the routine use of all of these agents in the treatment of patients who have metastatic disease, and this has led to improved survival for these patients. In earlier stage disease, oxaliplatin/5-FU-based chemotherapy has become a new standard of adjuvant therapy for many patients. Clinical research efforts are investigating the use of biologic agents along with chemotherapy for adjuvant treatment; it is hoped that this will translate into a greater cure rate for these patients.
